- Home
- EMO vs KROS Comparison
EMO vs KROS Comparison
Compare EMO & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMO
- KROS
- Stock Information
- Founded
- EMO 2011
- KROS 2015
- Country
- EMO United States
- KROS United States
- Employees
- EMO N/A
- KROS N/A
- Industry
- EMO Investment Managers
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- EMO Finance
- KROS Health Care
- Exchange
- EMO Nasdaq
- KROS Nasdaq
- Market Cap
- EMO 599.1M
- KROS 589.8M
- IPO Year
- EMO N/A
- KROS 2020
- Fundamental
- Price
- EMO $51.12
- KROS $11.82
- Analyst Decision
- EMO
- KROS Buy
- Analyst Count
- EMO 0
- KROS 11
- Target Price
- EMO N/A
- KROS $45.33
- AVG Volume (30 Days)
- EMO 27.1K
- KROS 1.9M
- Earning Date
- EMO 01-01-0001
- KROS 02-26-2025
- Dividend Yield
- EMO 6.70%
- KROS N/A
- EPS Growth
- EMO N/A
- KROS N/A
- EPS
- EMO N/A
- KROS N/A
- Revenue
- EMO N/A
- KROS $651,000.00
- Revenue This Year
- EMO N/A
- KROS $303.27
- Revenue Next Year
- EMO N/A
- KROS N/A
- P/E Ratio
- EMO N/A
- KROS N/A
- Revenue Growth
- EMO N/A
- KROS 8037.50
- 52 Week Low
- EMO $26.42
- KROS $9.78
- 52 Week High
- EMO $40.17
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- EMO 74.60
- KROS 22.59
- Support Level
- EMO $49.02
- KROS $10.95
- Resistance Level
- EMO $51.87
- KROS $11.63
- Average True Range (ATR)
- EMO 0.94
- KROS 0.84
- MACD
- EMO 0.50
- KROS 1.22
- Stochastic Oscillator
- EMO 86.44
- KROS 23.90
About EMO ClearBridge Energy Midstream Opportunity Fund Inc.
ClearBridge Energy Midstream Opportunity Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide long-term investors with a high level of total return with an emphasis on cash distributions.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.